Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.

Asco data suggest that the TROP2 ADC Merck & Co licensed from Kelun is at least as good as Gilead and Astra/Daiichi’s assets.

After generating unexpectedly positive TIGIT data Roche moves to launch a phase 3 trial.